The Division of Drug Information (DDI) is CDER's focal point for public inquiries. We serve the public by providing information on human drug products and drug product regulation by FDA.
Latest warning comes after elevated levels of lead were found in the product in Maryland
The FDA is working with the Maryland Department of Health and Mental Hygiene (DHMH) and other states to continue to warn consumers and caregivers not to use Eu Yan Sang (Hong Kong) Ltd.’s “Bo Ying compound” because of the possible lead poisoning risk associated with the product. This reminder comes after the Maryland’s DHMH found elevated levels of lead in these products.
The powdered product is marketed in retail outlets and online for use in infants and children for treatment of a variety of conditions including influenza, fever, sneezing, and nasal discharge. The product is labeled in Chinese and English.
Parents and caregivers are advised to not purchase or use “Bo Ying compound.” Anyone using this product or providing it to a child should immediately consult a health care professional.
For more information, please visit: Bo Ying compound
This is an automated message delivery system. Replying to this message will not reach DDI staff. If you have comments or questions, please contact us at: 1-888-INFO FDA (1-888-463-6332) or (301) 796-3400 from 8:00 am - 4:30 pm ET Monday - Friday. You can also email us at druginfo@fda.hhs.gov.
- For additional drug information, please visit the DDI Web page.
- For up-to-date drug information, follow the FDA’s Division of Drug Information on Twitter: FDA_Drug_Info.
- This service is provided to you at no charge by the U.S. Food & Drug Administration (FDA).
No hay comentarios:
Publicar un comentario